135 related articles for article (PubMed ID: 30904888)
1. Unusual first presentation of a metabolic disorder.
Strauss CE; Hann G
BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30904888
[TBL] [Abstract][Full Text] [Related]
2. Hepatorenal Tyrosinaemia: Impact of a Simplified Diet on Metabolic Control and Clinical Outcome.
Bärhold F; Meyer U; Neugebauer AK; Thimm EM; Lier D; Rosenbaum-Fabian S; Och U; Fekete A; Möslinger D; Rohde C; Beblo S; Hochuli M; Bogovic N; Korpel V; Dahl SV; Mayorandan S; Fischer A; Freisinger P; Dokoupil K; Heddrich-Ellerbrok M; Jörg-Streller M; van Teeffelen-Heithoff A; Lahl J; Das AM
Nutrients; 2020 Dec; 13(1):. PubMed ID: 33396520
[No Abstract] [Full Text] [Related]
3. Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment.
Schlump JU; Perot C; Ketteler K; Schiff M; Mayatepek E; Wendel U; Spiekerkoetter U
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S223-5. PubMed ID: 18500574
[TBL] [Abstract][Full Text] [Related]
4. Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC).
Pronicka E; Rowinska E; Bentkowski Z; Zawadzki J; Holme E; Lindstedt S
J Inherit Metab Dis; 1996; 19(2):234-8. PubMed ID: 8739974
[No Abstract] [Full Text] [Related]
5. Experience with NTBC therapy in hereditary tyrosinaemia type I: an alternative to liver transplantation.
Joshi SN; Venugopalan P
Ann Trop Paediatr; 2004 Sep; 24(3):259-65. PubMed ID: 15479577
[TBL] [Abstract][Full Text] [Related]
6. Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience.
Zeybek AC; Kiykim E; Soyucen E; Cansever S; Altay S; Zubarioglu T; Erkan T; Aydin A
Pediatr Int; 2015 Apr; 57(2):281-9. PubMed ID: 25223216
[TBL] [Abstract][Full Text] [Related]
7. Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
Gissen P; Preece MA; Willshaw HA; McKiernan PJ
J Inherit Metab Dis; 2003; 26(1):13-6. PubMed ID: 12872835
[TBL] [Abstract][Full Text] [Related]
8. New treatment for tyrosinaemia.
Lancet; 1992 Oct; 340(8823):822-3. PubMed ID: 1357248
[No Abstract] [Full Text] [Related]
9. Neonatal screening for hereditary tyrosinaemia: are we there yet?
Hadžić N; Vara R
Arch Dis Child; 2015 Aug; 100(8):720-1. PubMed ID: 25957320
[No Abstract] [Full Text] [Related]
10. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.
Santra S; Baumann U
Expert Opin Pharmacother; 2008 May; 9(7):1229-36. PubMed ID: 18422479
[TBL] [Abstract][Full Text] [Related]
11. [Lectin-reactive alpha-fetoprotein in tyrosinaemia type I].
Baumann U; Duhme V; Knerr I; Pronicka E; Auth MK; Voit PT
Klin Padiatr; 2005; 217(3):142-6. PubMed ID: 15858705
[TBL] [Abstract][Full Text] [Related]
12. Peripheral neuropathy as the presenting feature of tyrosinaemia type I and effectively treated with an inhibitor of 4-hydroxyphenylpyruvate dioxygenase.
Gibbs TC; Payan J; Brett EM; Lindstedt S; Holme E; Clayton PT
J Neurol Neurosurg Psychiatry; 1993 Oct; 56(10):1129-32. PubMed ID: 8410015
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous porphyria in a neonate with tyrosinaemia type 1.
Vanden Eijnden S; Blum D; Clercx A; Goyens P; De Laet C; Vamos E
Eur J Pediatr; 2000 Jul; 159(7):503-6. PubMed ID: 10923223
[TBL] [Abstract][Full Text] [Related]
14. Plasma antioxidant capacity in two cases of tyrosinaemia type 1: one case treated with NTBC.
Bird S; Miller NJ; Collins JE; Rice-Evans CA
J Inherit Metab Dis; 1995; 18(2):123-6. PubMed ID: 7564225
[No Abstract] [Full Text] [Related]
15. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I.
Grompe M; Lindstedt S; al-Dhalimy M; Kennaway NG; Papaconstantinou J; Torres-Ramos CA; Ou CN; Finegold M
Nat Genet; 1995 Aug; 10(4):453-60. PubMed ID: 7545495
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.
Lindstedt S; Holme E; Lock EA; Hjalmarson O; Strandvik B
Lancet; 1992 Oct; 340(8823):813-7. PubMed ID: 1383656
[TBL] [Abstract][Full Text] [Related]
17. Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1.
De Laet C; Munoz VT; Jaeken J; François B; Carton D; Sokal EM; Dan B; Goyens PJ
Dev Med Child Neurol; 2011 Oct; 53(10):962-4. PubMed ID: 21745202
[No Abstract] [Full Text] [Related]
18. Tyrosinemia type 1 and irreversible neurologic crisis after one month discontinuation of nitisone.
Önenli Mungan N; Yıldızdaş D; Kör D; Horoz ÖÖ; İncecik F; Öktem M; Sander J
Metab Brain Dis; 2016 Oct; 31(5):1181-3. PubMed ID: 27188289
[TBL] [Abstract][Full Text] [Related]
19. Reversibility of cirrhotic regenerative liver nodules upon NTBC treatment in a child with tyrosinaemia type I.
Crone J; Möslinger D; Bodamer OA; Schima W; Huber WD; Holme E; Stöckler Ipsiroglu S
Acta Paediatr; 2003 May; 92(5):625-8. PubMed ID: 12839296
[TBL] [Abstract][Full Text] [Related]
20. NTBC as palliative treatment in chronic tyrosinaemia type I.
Ros J; Vilaseca MA; Lambruschini N; Mas A; Lindstedt S; Holme E
J Inherit Metab Dis; 1999 Jun; 22(5):665-6. PubMed ID: 10399099
[No Abstract] [Full Text] [Related]
[Next] [New Search]
